Apothecary Pharma Recalls Compounded Tirzepatide Injections Due to Sterility Concerns

Apothecary Pharma LLC has initiated a Class II voluntary recall of 22 vials of compounded tirzepatide injections across the U.S. due to a lack of assurance of sterility. Tirzepatide is the active ingredient in FDA-approved medications like Zepbound and Mounjaro. The FDA had previously issued a warning letter to the company in December 2025 citing deficiencies in sterile drug product manufacturing.